Ascendis registers Phase 3 trial of navepegritide in hypochondroplasia
The study, led by Ascendis Pharma A/S, plans to enroll 81 children and adolescents with hypochondroplasia and has a planned start date of November 2026. It is a randomized, double-blind, placebo-controlled trial that plans to reach primary completion in October 2028.
Primary source
ClinicalTrials.gov registry record, November 4, 2026
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia
Read the source: A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation